Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2023

06-01-2023 | Insulins | Letter to the Editor

Glucagon-like peptide-1 receptor agonists for improving cardiorenal outcomes in type 1 diabetes mellitus?

Authors: Djordje S. Popovic, Anca Pantea Stoian, Nikolaos Papanas

Published in: Endocrine | Issue 1/2023

Login to get access

Excerpt

Dear Editor-in-Chief, …
Literature
1.
2.
3.
4.
5.
Metadata
Title
Glucagon-like peptide-1 receptor agonists for improving cardiorenal outcomes in type 1 diabetes mellitus?
Authors
Djordje S. Popovic
Anca Pantea Stoian
Nikolaos Papanas
Publication date
06-01-2023
Publisher
Springer US
Published in
Endocrine / Issue 1/2023
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-022-03294-3

Other articles of this Issue 1/2023

Endocrine 1/2023 Go to the issue

Original Article

The clinical characteristics of patients with normotension in pheochromocytomas and paragangliomas

Original Article

The prognostic utility of serum thyrotropin in hospitalized Covid-19 patients: statistical and machine learning approaches

Letter to the Editor

Letter to Editor: Call for review of European Society of Endocrinology guidelines for symptomatic hyponatraemia

Original Article

Predicting malignancy in thyroid nodules based on conventional ultrasound and elastography: the value of predictive models in a multi-center study

Original Article

Characterization of circulating immune cells and correlation with Tie2/Angiopoietins level in well differentiated neuroendocrine gastroenteropancreatic tumors: a cross-sectional analysis

Original Paper

Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits